Medical Xpress July 12, 2021
Scott Lafee, University of California - San Diego

Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.

The study findings could measurably change how researchers sift through big data to find meaningful information with significant benefit to patients, the pharmaceutical industry and the nation’s health care systems.

“Academic labs and pharmaceutical and biotech companies have access to unlimited amounts of ‘big data’ and better tools than ever to analyze such data. However, despite these incredible advances in technology, the success rates in discovery are lower today than in the 1970s,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma, Pharma / Biotech, Technology
March Fundraising Roundup: 7 Provider Tech Startups That Closed Rounds This Month
Google DeepMind unveils ‘superhuman’ AI system that excels in fact-checking, saving costs and improving accuracy
Katie Couric Talks Colon Cancer, Health Equity And AI
5 tips on AI adoption from a frontline physician champion
Survey of Oncologists Finds Agreement, Concerns Over AI Use

Share This Article